A Phase 1, Double-blind, Placebo-Controlled, Single Oral Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTI-2088 Tablet in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs HTI-2088 (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Hengrui Therapeutics
- 31 Aug 2018 Biomarkers information updated
- 10 Nov 2017 Status changed from recruiting to completed.
- 08 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Sep 2017.